Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
S100A11 pseudogene 6 (S100A11P6) refers to a genomic sequence highly homologous to the S100 calcium-binding protein A11 gene but is classified as a pseudogene—meaning it does not produce a functional protein product. It has no documented biological activity, therapeutic targeting, or disease association. In drug discovery or molecular biology, S100A11P6 is not considered a meaningful protein target. The biologically active member is S100A11, a calcium-binding protein involved in cellular signaling, motility, and implicated in cancer and inflammatory diseases[1][3][5]. There is no evidence supporting pseudogenes from the S100A11 family (including S100A11P6) as drug targets or biomarkers in the scientific literature.\n\nIn summary: \nS100A11 pseudogene 6 is not a receptor, enzyme, or classical molecular target, but a genomic relic of S100A11. For actionable biological and pharmacological information, refer to S100 calcium-binding protein A11 (S100A11), not S100A11P6[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on S100A11 pseudogene 6 (S100A11P6).